当前位置: X-MOL 学术CNS Drugs › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.
CNS Drugs ( IF 7.4 ) Pub Date : 2019-11-01 , DOI: 10.1007/s40263-019-00678-4
Natasha Ivanova 1 , Jana Tchekalarova 1
Affiliation  

Epilepsy is one of the most prevalent neurological diseases and although numerous novel anticonvulsants have been approved, the proportion of patients who are refractory to medical treatment of seizures and have progressive co-morbidities such as cognitive impairment and depression remains at about 20-30%. In the last decade, extensive research has identified a therapeutic capacity of the components of the brain renin-angiotensin system (RAS) in seizure- and epilepsy-related phenomena. Alleviating the activity of RAS in the central nervous system is considered to be a potential adjuvant strategy for the treatment of numerous detrimental consequences of epileptogenesis. One of the main advantages of RAS is associated with its modulatory influence on different neurotransmitter systems, thereby exerting a fine-tuning control mechanism for brain excitability. The most recent scientific findings regarding the involvement of the components of brain RAS show that angiotensin II (Ang II), angiotensin-converting enzyme (ACE), Ang II type 1 (AT1) and type 2 (AT2) receptors are involved in the control of epilepsy and its accompanying complications, and therefore they are currently of therapeutic interest in the treatment of this disease. However, data on the role of different components of brain RAS on co-morbid conditions in epilepsy, including hypertension, are insufficient. Experimental and clinical findings related to the involvement of Ang II, ACE, AT1, and AT2 receptors in the control of epilepsy and accompanying complications may point to new therapeutic opportunities and adjuvants for the treatment of common co-morbid conditions of epilepsy.

中文翻译:

抑制脑肾素-血管紧张素系统治疗癫痫共病的潜在治疗能力。

癫痫病是最流行的神经系统疾病之一,尽管已批准了许多新型抗惊厥药,但对癫痫病的药物治疗无效且具有并发合并症(例如认知障碍和抑郁症)的患者比例仍约为20-30%。在过去的十年中,广泛的研究已经确定了在发作和癫痫相关现象中脑肾素-血管紧张素系统(RAS)的成分的治疗能力。减轻中枢神经系统中RAS的活性被认为是治疗癫痫发生的许多有害后果的潜在辅助策略。RAS的主要优点之一是其对不同神经递质系统的调节作用,从而对大脑的兴奋性施加微调控制机制。有关大脑RAS成分参与的最新科学发现表明,血管紧张素II(Ang II),血管紧张素转化酶(ACE),Ang II 1型(AT1)和2型(AT2)受体参与了控制癫痫及其伴随的并发症,因此它们目前在该疾病的治疗中具有治疗意义。但是,关于脑RAS不同成分在癫痫病合并症(包括高血压)中的作用的数据不足。与Ang II,ACE,AT1,
更新日期:2019-11-01
down
wechat
bug